Differential Kat3 Coactivator Usage Regulates Brain Metabolism and Neuronal Differentiation
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
INTRODUCTION: Our previous work has demonstrated significant effects on the oxidative stress response, mitochondrial function, and oxidative phosphorylation in the livers and intestines of p300 S89A knockin (S89AKI) mice. We now show that this mutation is also associated with brain metabolic defects and neuronal differentiation.
METHODS: p300 S89A edited P19 cells, and S89AKI mice demonstrated metabolic and neuronal differentiation defects based on proteomic, cell biological and PET imaging studies.
RESULTS: The metabolic and differentiation defects associated with the p300 S89A knockin mutation could be corrected both in vitro and in vivo utilizing the small molecule CBP/beta-catenin antagonist ICG-001.
CONCLUSION: Rebalancing the equilibrium between CBP/β-catenin versus p300/β-catenin associated transcription, utilizing the small molecule CBP/beta-catenin antagonist ICG-001, enhances mitochondrial oxidative phosphorylation, metabolic function, and neuronal differentiation and may be able to ameliorate the cognitive decline seen in neurodegenerative disorders, including Alzheimer's Disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 2023 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Current molecular pharmacology - 17(2023), 1 vom: 07., Seite e170823219875 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Poku, Erasmus Kofi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Beta Catenin |
|---|
| Anmerkungen: |
Date Completed 21.11.2023 Date Revised 21.11.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1874467217666230817092415 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360930085 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360930085 | ||
| 003 | DE-627 | ||
| 005 | 20231226084052.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1874467217666230817092415 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1203.xml |
| 035 | |a (DE-627)NLM360930085 | ||
| 035 | |a (NLM)37594155 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Poku, Erasmus Kofi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Differential Kat3 Coactivator Usage Regulates Brain Metabolism and Neuronal Differentiation |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.11.2023 | ||
| 500 | |a Date Revised 21.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a INTRODUCTION: Our previous work has demonstrated significant effects on the oxidative stress response, mitochondrial function, and oxidative phosphorylation in the livers and intestines of p300 S89A knockin (S89AKI) mice. We now show that this mutation is also associated with brain metabolic defects and neuronal differentiation | ||
| 520 | |a METHODS: p300 S89A edited P19 cells, and S89AKI mice demonstrated metabolic and neuronal differentiation defects based on proteomic, cell biological and PET imaging studies | ||
| 520 | |a RESULTS: The metabolic and differentiation defects associated with the p300 S89A knockin mutation could be corrected both in vitro and in vivo utilizing the small molecule CBP/beta-catenin antagonist ICG-001 | ||
| 520 | |a CONCLUSION: Rebalancing the equilibrium between CBP/β-catenin versus p300/β-catenin associated transcription, utilizing the small molecule CBP/beta-catenin antagonist ICG-001, enhances mitochondrial oxidative phosphorylation, metabolic function, and neuronal differentiation and may be able to ameliorate the cognitive decline seen in neurodegenerative disorders, including Alzheimer's Disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CBP | |
| 650 | 4 | |a ICG-001 | |
| 650 | 4 | |a Kat3. | |
| 650 | 4 | |a Metabolism | |
| 650 | 4 | |a Neurodegeneration | |
| 650 | 4 | |a p300 | |
| 650 | 7 | |a beta Catenin |2 NLM | |
| 700 | 1 | |a Ono, Masaya |e verfasserin |4 aut | |
| 700 | 1 | |a Higuchi, Yusuke |e verfasserin |4 aut | |
| 700 | 1 | |a Chea, Junie |e verfasserin |4 aut | |
| 700 | 1 | |a Melendez, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Teo, Jia-Ling |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen, Cu |e verfasserin |4 aut | |
| 700 | 1 | |a Chimge, Nyam-Osor |e verfasserin |4 aut | |
| 700 | 1 | |a Kahn, Michael |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current molecular pharmacology |d 2008 |g 17(2023), 1 vom: 07., Seite e170823219875 |w (DE-627)NLM185149499 |x 1874-4702 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2023 |g number:1 |g day:07 |g pages:e170823219875 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1874467217666230817092415 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2023 |e 1 |b 07 |h e170823219875 | ||